Integrated reverse network toxicology and experimental validation identify PTP4A3 as a key target of Benzo[a]pyrene in prostate cancer.
It is suggested that benzo[a]pyrene could contribute to the acquisition of pro-invasive phenotypes in prostate epithelial cells and potentially to prostate carcinogenesis, probably through upregulating PTP4A3 to activate matrix remodeling programs.